Metastatic Breast Cancer Mbc clinical trials

Explore recruiting metastatic breast cancer mbc clinical trials.

Recruiting metastatic breast cancer mbc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Breast Cancer Mbc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)

Poland, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

ETIC-LM_Multicentric single arm phase II study evaluating the Efficacy of association of Tucatinib, capecitabine and Intra-CSF trastuzumab in HER2 amplified breast cancer patients with Leptomeningeal Metastases.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease

Italy, Spain, Sweden, France, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients considered resistant to trastuzumab + pertuzumab + taxane due to early relapse. “TRANSCENDER Study”

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluating the Diagnostic Performance of Human Epidermal Growth Factor Receptor 2 (HER2) targeted Positron Emission Tomography and Computed Tomography (PET/CT) with 68Ga-ABS011 in metastatic Breast Cancer (mBC) and other metastatic solid carcinomas.

Belgium, Austria

Phase II and Phase III (Integrated) EU CTIS Study details

Metastatic Breast Cancer Mbc trials by city

Metastatic Breast Cancer Mbc in Toronto Metastatic Breast Cancer Mbc in Vancouver Metastatic Breast Cancer Mbc in Montreal Metastatic Breast Cancer Mbc in Calgary Metastatic Breast Cancer Mbc in Edmonton Metastatic Breast Cancer Mbc in Ottawa Metastatic Breast Cancer Mbc in Winnipeg Metastatic Breast Cancer Mbc in Quebec City Metastatic Breast Cancer Mbc in Hamilton Metastatic Breast Cancer Mbc in Kitchener Metastatic Breast Cancer Mbc in London Metastatic Breast Cancer Mbc in Halifax Metastatic Breast Cancer Mbc in New York Metastatic Breast Cancer Mbc in Los Angeles Metastatic Breast Cancer Mbc in Chicago Metastatic Breast Cancer Mbc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease